Cyclotek

Cyclotek is a leading radiopharmaceutical manufacturer in Australia and New Zealand. The company specializes in producing novel positron emission tomography (PET) tracers that provide patient-specific insights into disease states, enabling earlier diagnosis, more accurate assessment of disease extent, and improved treatment planning and monitoring. Cyclotek's product portfolio includes 18F-FP-CIT, a PET tracer used for diagnosing Parkinson's disease, and 18F-Florbetaben (NeuraCeq), an imaging agent for estimating β-amyloid neuritic plaque density in the brain, aiding in the diagnosis of Alzheimer's disease. In June 2022, Cyclotek validated the manufacturing of 18F-Florbetaben for clinical trials and the Special Access Scheme in Australia and New Zealand.

Cyclotek has also validated the manufacture of 18F-PI-2620, a PET tracer targeting tau protein aggregates associated with Alzheimer's disease and other neurodegenerative disorders. In collaboration with Life Molecular Imaging, Cyclotek supplies 18F-PI-2620 for clinical trials investigating its effectiveness in diagnosing and monitoring dementia.

In February 2022, through a joint venture with ANSTO called Applied Molecular Therapies (AMT), Cyclotek obtained a license for the GMP manufacture of 177Lu(n.c.a.)-PSMA-Therapy, a targeted radiopharmaceutical therapy for treating metastatic prostate cancer. This therapy binds to the prostate-specific membrane antigen (PSMA) expressed by prostate cancer cells, delivering radiation to the tumor sites.

In July 2023, Cyclotek was involved in supplying 18F-Florbetaben and 18F-PI-2620 to a Monash University-led study investigating the safety and efficacy of sodium selenate in treating behavioral variant frontotemporal dementia (bvFTD). The PET tracers assisted in patient selection and monitoring disease progression.